Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

Patient expectations and shared decision making in aRCC

PD-1–refractory advanced melanoma: how do we get to the finish line?

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma

Highlights in melanoma from ASCO 2024

Immunotherapy significantly increases the number of patients free from bowel cancer

Encouraging results using mismatched unrelated donors in stem cell transplantation

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy